… Our leading intellectual property portfolio protects our Axiomer ® ADAR-mediated RNA editing platform technology and … patent protection related to its RNA editing platform, Axiomer ® , including more than 11 published patent families, … its IP estate around ADAR-mediated RNA editing. About Axiomer ® ProQR is pioneering a next-generation RNA base …
… transformative RNA therapies based on its proprietary Axiomer ® RNA editing technology platform, today reported its … pleased with the continued progress in advancing our Axiomer ® RNA editing platform and believe we’re only at the … In November ProQR announced its IP estate surrounding its Axiomer ® RNA editing platform was further strengthened by: …
… the event, the Company will showcase its proprietary Axiomer ® RNA-editing technology platform, announce initial … and mentored over 50 Ph.D. and M.S. degree students. About Axiomer ® ProQR is pioneering a next-generation RNA base editing technology called Axiomer ® , which could potentially yield a new class of …
… Announces Year End 2024 Operating and Financial Results Axiomer™ ADAR-mediated RNA editing pipeline advancing across … transformative RNA therapies based on its proprietary Axiomer RNA editing technology platform, today reported its …
… targeting NTCP for cholestatic diseases to be first ProQR Axiomer™ RNA editing program to enter the clinic Company to … for cardiovascular diseases, and progress made across the Axiomer platform €89.4 million cash and cash equivalents as …
… transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the … perspective in guiding the Company in the translation of Axiomer, our leading RNA editing platform technology, to the …
… Cardiovascular Disease targeting B4GALT1 Development of Axiomer ® RNA base editing technology platform continues … with successful defense of opposition against a key Axiomer patent protecting ADAR-mediated RNA editing … against our strategy to accelerate the development of Axiomer,” said Daniel A. de Boer, Chief Executive Officer of …
… transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced an … in MECP2 gene, and is based on ProQR’s proprietary Axiomer RNA editing platform. Axiomer can target many …
… strategy to focus on accelerating the development of Axiomer ® RNA base-editing technology platform across … RNA editing technology – Accelerate development of the Axiomer ® RNA base-editing technology platform, including an … The Company will accelerate the development of its Axiomer ® RNA editing platform and pipeline activities and …